Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention Academic Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Atherectomy, Coronary
  • Coronary Disease
  • Hemorrhage
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Membrane Glycoproteins

abstract

  • This first clinical investigation of Integrelin during routine, elective, low- and high-risk coronary intervention supports the potential efficacy of Integrelin in routine coronary interventions. Pharmacodynamic analyses demonstrate that profound and sustained inhibition of platelet function is achieved, although a higher bolus dose may be required. Definitive assessment of efficacy and safety will need to await a large-scale study powered to achieve statistical significance.

publication date

  • April 15, 1995

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7697843

Additional Document Info

start page

  • 2151

end page

  • 7

volume

  • 91

number

  • 8